Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Boehringer-Ingelheim"

83 News Found

Torrent Pharma inks agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands
News | December 05, 2024

Torrent Pharma inks agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands

The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market


Boehringer Ingelheim launches next generation poultry vaccine in India
Healthcare | November 26, 2024

Boehringer Ingelheim launches next generation poultry vaccine in India

This is recommended for in-ovo vaccination of 18 to 19-day-old embryonated chicken eggs and one-day old chickens to protect against the virulent Marek’s disease


Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn
News | July 31, 2024

Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn

Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio


Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis
Clinical Trials | June 09, 2024

Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis

New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH


Boehringer Ingelheim introduces NexGard Spectra for dogs in India
News | April 22, 2024

Boehringer Ingelheim introduces NexGard Spectra for dogs in India

NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs


Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows achieved groundbreaking results in liver disease due to MASH
Clinical Trials | February 28, 2024

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows achieved groundbreaking results in liver disease due to MASH

Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis


Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
News | January 03, 2024

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes


Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India
News | August 19, 2023

Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India

This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes


Boehringer Ingelheim receives FDA approval for Senvelgo to treat diabetes in cat
Drug Approval | August 16, 2023

Boehringer Ingelheim receives FDA approval for Senvelgo to treat diabetes in cat

Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus


Boehringer Ingelheim receives FDA approval for NexGard Plus
News | July 22, 2023

Boehringer Ingelheim receives FDA approval for NexGard Plus

The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio